台灣癌症登記長表實作指引 (Taiwan Cancer Registry Long Form Implementation Guide)
0.1.1 - ci-build
台灣癌症登記長表實作指引 (Taiwan Cancer Registry Long Form Implementation Guide) - Local Development build (v0.1.1) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions
| Official URL: https://hapi.fhir.tw/fhir/ValueSet/ssf-2-leukemia-valueset | Version: 0.1.1 | |||
| Active as of 2024-08-01 | Computable Name: SSF2leukemiaVS | |||
Assessment of molecular studies in leukemia Value Set
References
This value set is not used here; it may be used elsewhere (e.g. specifications and/or implementations that use this content)
Generated Narrative: ValueSet ssf-2-leukemia-valueset
https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem
Generated Narrative: ValueSet
Expansion based on codesystem SSF2 白血病-白血病分子生物學檢查的評估代碼系統 v0.1.1 (CodeSystem)
This value set contains 33 concepts
| Code | System | Display |
| 000 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | 正常 |
| 001 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | AML with RUNX1-RUNX1T1 |
| 002 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | AML with CBFB-MYH11 |
| 003 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | Acute promyelocytic leukemia with PML-RARA |
| 004 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | AML with KMT2A-MLLT3 |
| 005 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | AML with DEK-NUP214 |
| 006 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | AML with GATA2, MECOM |
| 007 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | AML(megakaryoblastic) with RBM15-MKL1 |
| 008 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | AML with mutated NPM1 |
| 009 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | AML with biallelic mutation of CEBPA |
| 010 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | AML with mutated FLT3/ITD |
| 011 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | AML with mutated FLT3/TKD |
| 012 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | AML with MLL-PTD (partial tandem duplication) |
| 013 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | AML with BCR-ABL1 |
| 021 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | B lymphoblastic leukemia/lymphoma with BCR-ABL1 |
| 022 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | B-lymphoblastic leukemia/lymphoma with KMT2A-rearranged |
| 023 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | B-lymphoblastic leukemia/lymphoma with ETV6-RUNX1 (TEL-AML1) |
| 024 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | B-lymphoblastic leukemia/lymphoma with IGH/IL3 |
| 025 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | B-lymphoblastic leukemia/lymphoma with TCF3-PBX1 (E2A-PBX1) |
| 041 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | Mixed phenotype acute leukemia with BCR-ABL1 |
| 042 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | Mixed-phenotype acute leukemia with KMT2A-rearranged |
| 051 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | Chronic myelogenous leukemia BCR-ABL1 positive |
| 052 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | JAK2 V617F mutation |
| 053 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | Myeloid and lymphoid neoplasms with PDGFRA rearrangement |
| 054 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | Myeloid and lymphoid neoplasms with PDGFRB rearrangement |
| 055 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | Myeloid and lymphoid neoplasms with FGFR1 rearrangement |
| 090 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | (1) 一種異常，其他上述未列之分子檢驗異常 (2) 二種異常，其中一種非上述之分子檢驗異常 (3) 二種異常，二種皆非上述之分子檢驗異常 |
| 091 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | 同時有兩種(含)以上上述之分子檢驗異常 |
| 092 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | 同時有三種(含)以上分子檢驗異常 (1) 三種(含)以上異常，其中一種以上非上述之分子檢驗異常 (2)三種(含)以上異常，皆非上述之分子檢驗異常 |
| 8XX | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | Molecular study after chemotherapy or immunotherapy or target therapy |
| 988 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | 不適用。(1) ICD-O-3 M-9811-9837 (EXCEPT C42.0, 42.1, 42.4) |
| 998 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | 有執行分子生物學檢查，但結果無法判斷 |
| 999 | https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem | (1) 病歷未記載或不詳 (2) 未執行分子生物學檢查 |
Explanation of the columns that may appear on this page:
| Level | A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies |
| System | The source of the definition of the code (when the value set draws in codes defined elsewhere) |
| Code | The code (used as the code in the resource instance) |
| Display | The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application |
| Definition | An explanation of the meaning of the concept |
| Comments | Additional notes about how to use the code |